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Abstract
Background—Implications of different adiposity measures on cardiovascular disease aetiology 
remain unclear. In this paper we quantify and contrast causal associations of central adiposity 
(waist:hip ratio adjusted for BMI (WHRadjBMI)) and general adiposity (body mass index 
(BMI)) with cardiometabolic disease. 
Methods—97 independent single nucleotide polymorphisms (SNPs) for BMI and 49 SNPs for 
WHRadjBMI were used to conduct Mendelian randomization analyses in 14 prospective studies 
supplemented with CHD data from CARDIoGRAMplusC4D (combined total 66,842 cases),
stroke from METASTROKE (12,389 ischaemic stroke cases), type 2 diabetes (T2D) from 
DIAGRAM (34,840 cases), and lipids from GLGC (213,500 participants) consortia. Primary 
outcomes were CHD, T2D, and major stroke subtypes; secondary analyses included 18 
cardiometabolic traits. 
Results—Each one standard deviation (SD) higher WHRadjBMI (1SD~0.08 units) associated 
with a 48% excess risk of CHD (odds ratio [OR] for CHD: 1.48; 95%CI: 1.28-1.71), similar to 
findings for BMI (1SD~4.6kg/m2; OR for CHD: 1.36; 95%CI: 1.22-1.52). Only WHRadjBMI 
increased risk of ischaemic stroke (OR 1.32; 95%CI 1.03-1.70). For T2D, both measures had 
large effects: OR 1.82 (95%CI 1.38-2.42) and OR 1.98 (95%CI 1.41-2.78) per 1SD higher 
WHRadjBMI and BMI respectively. Both WHRadjBMI and BMI were associated with higher
left ventricular hypertrophy, glycaemic traits, interleukin-6, and circulating lipids. WHRadjBMI 
was also associated with higher carotid intima-media thickness (39%; 95%CI: 9%-77% per 
1SD).
Conclusions—Both general and central adiposity have causal effects on CHD and T2D. Central 
adiposity may have a stronger effect on stroke risk. Future estimates of the burden of adiposity 
on health should include measures of central and general adiposity.  
Key Words: body mass index; Mendelian randomization 
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Clinical Perspective
What is new? 
? This large-scale genetic analysis presents the most comprehensive causal assessment of 
adiposity with cardiometabolic diseases to date, including new data for stroke subtypes 
from METASTROKE and novel cardiometabolic traits including ECG measures and 
CIMT.  
? We find that waist:hip ratio adjusted for BMI, a measure of central body fat distribution 
that aims to be independent of general adiposity, is causally related to higher risks of 
coronary heart disease, ischaemic stroke and type 2 diabetes and a multitude of 
cardiometabolic traits. 
? Our findings also reinforce existing evidence on the causal relevance of general adiposity 
(BMI) to these diseases and provide more precise estimates.
What are the clinical implications? 
? Both the amount of adiposity and its distribution play important roles in influencing 
multiple cardiometabolic traits and the development of cardiometabolic diseases. 
? Furthermore, our findings indicate that body fat distribution has multiple causal roles in 
disease that are independent of general adiposity.  
? This suggests that physicians should pay attention to measures of adiposity beyond BMI 
as measurement of such traits may identify patients at risk of cardiometabolic disease and 
provides opportunities to the scientific community to identify novel approaches to disease 
prevention.  
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Observational studies have identified associations between adiposity and the risk of developing 
incident coronary heart disease (CHD), stroke and type 2 diabetes mellitus (T2D)1, 2. Many
observational studies report consistent results with different measures of adiposity; for example 
the Emerging Risk Factors Collaboration found similar associations with both general adiposity 
measured via body mass index (BMI) and central adiposity measured via waist to hip ratio 
(WHR) for CHD and ischaemic stroke1. The association of different adiposity measures with 
T2D has also been found to be similar2. 
 However, other studies have suggested that central adiposity, measured as either WHR or
waist circumference (WC), may have stronger associations with cardiovascular disease. For 
example, INTERHEART found a stronger association for WHR with myocardial infarction (MI) 
than BMI, and the association of WHR with MI persisted after adjustment for BMI3. The Million 
Women Study found that WC increased CHD risk within BMI categories (and vice versa) again
suggesting each is independently associated with CHD4.  Furthermore, INTERSTROKE found 
WHR to be more strongly associated with stroke risk than BMI5. While these studies have 
attempted to separate the independent effects of general and central adiposity, this remains 
challenging in observational studies due to the high degree of correlation between adiposity 
measures. Another problem is that adiposity measures may differ in their reproducibility; for 
example BMI is less affected by regression dilution bias – a bias to the null resulting from 
measurement error - than WHR 6. In addition, all measures of adiposity suffer from confounding 
due to underlying ill-health at low or sub-clinical levels, because many chronic conditions lead to 
weight loss7-9.  Consequently it is very difficult, if not impossible, to quantify the true 
independent effects of different measures of adiposity in observational studies alone. 
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Whilst Mendelian randomization (MR) studies minimise bias from traditional sources 
such as confounding, regression dilution bias and reverse causation, they may be susceptible to 
bias from pleiotropy (association of genetic variants with more than one variable). Pleiotropy can 
be vertical due to multiple downstream effects that follow the SNP effect on the exposure of 
interest, but this does not compromise MR assumptions. Alternatively, pleiotropy can be 
horizontal, whereby the SNP or instrument affects pathways other than those of the exposure of 
interest and could therefore invalidate the MR assumption that the SNP only affects the outcome 
through the exposure of interest, potentially leading to biased causal estimates. With multi-SNP 
instruments, there is a chance that pleiotropic effects might become balanced such that causal 
inference regarding the exposure is possible. In this study we perform MR analyses of BMI and 
WHR together with recently developed methods that are robust to horizontal pleiotropy under 
additional assumptions (Supplemental Figure 1).  We therefore employ MR-Egger regression to 
provide a test for unbalanced pleiotropy and a causal estimate of exposure on outcome in its 
presence10, 11. In addition we use the weighted median estimator which can give valid estimates 
even in the presence of horizontal pleiotropy provided at least 50 per cent of the information in 
the analysis comes from variants that are valid instruments, and has the advantage of retaining 
greater precision in the estimates compared to MR-Egger12. 
 This manuscript represents the most comprehensive assessment of the causal role of 
adiposity on CHD, stroke and T2D to date. It contrasts the causal effects of central adiposity 
(waist:hip ratio adjusted for BMI (WHRadjBMI) from general adiposity (BMI) on multiple 
cardiovascular outcomes: new CHD events from 14 prospective studies/ RCTs in addition to data
publicly available from the CARDIOGRAMplusC4D13 increasing CHD cases to 66,842,
multiple stroke subtypes using data from METASTROKE14 and T2D from DIAGRAM15. We
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present the largest number of cardiometabolic traits ever examined in a MR analysis of adiposity  
including lipids from the Global Lipids Genetic Consortium (GLGC; 213,500 participants)16 and 
many novel intermediate disease end points, including electrocardiogram (ECG) measures of left 
ventricular hypertrophy, carotid intima media thickness (CIMT) as a measure of sub-clinical 
atherosclerosis, as well as markers of renal and lung disease.  We build distinct multi-SNP 
genetic instruments for each adiposity measure using the most comprehensive repertoire 
available from recent genome-wide association (GWA) studies17, 18,  with 97 SNPs for BMI and 
49 SNPs for WHRadjBMI, thereby more than doubling the phenotypic variance explained in 
some earlier MR studies19-23. 
Methods
Study selection and inclusion of participants
We include individual participant data from 10 studies in the University College London – 
London School of Hygiene and Tropical Medicine – Edinburgh - Bristol (UCLEB) consortium 
(see Supplemental Table 1 for study details). We include summary data from a further four 
studies (Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT), Health and Retirement Study 
(HRS), Netherlands Epidemiology of Obesity (NEO) and Prospective Study of Pravastatin in the 
Elderly at Risk (PROSPER)), and summary data from four consortia (CARDIoGRAMplusC4D, 
METASTROKE, DIAGRAM, Global Lipids Genetics Consortium (GLGC)) (see Appendix). All 
participating studies received approval from local institutional review boards or ethics 
committees. All participants gave informed consent. 
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Clinical Outcomes
Supplemental Table 2 provides details of CHD ascertainment and number of events by study. 
In UCLEB studies the primary outcome was combined prevalent or incident CHD defined as 
fatal or non-fatal myocardial infarction, or a coronary revascularisation procedure, but excluding 
angina. In the majority of studies events were validated (e.g. hospital episode statistics, 
clinical/laboratory measurements, review of primary care medical records). 
CARDIoGRAMplusC4D used standard criteria for defining cases of CAD and myocardial 
infarction with some studies including angiography-confirmed stenosis and stable or unstable 
angina13. METASTROKE define stroke as a typical clinical syndrome with radiological 
confirmation; subtyping was done with the Trial of Org 10172 in Acute Stroke Treatment 
(TOAST) classification system14. We include all ischaemic stroke, three sub-types of ischaemic 
stroke (large-vessel disease, small-vessel disease and cardioembolic stroke) and haemorrhagic 
stroke. T2D definitions follow DIAGRAM24.
Cardiometabolic traits
For analysis of individual participant data studies, data on sex, age, measured standing height, 
weight, waist circumference and hip circumference were used to derive BMI and WHRadjBMI 
traits. WHRadjBMI was calculated by generating the predicted residuals from the linear 
regression of WHR on BMI. Biomarkers included in analyses were grouped into the following 
categories; Lipids (triglycerides, HDL-C and LDL-C), inflammation (IL-6), lung function (ratio 
of FEV1 to FVC), metabolic (glucose, insulin and albumin), renal (creatinine, estimated 
glomerular filtration rate (EGFR), MDRD) and systolic blood pressure. The following 
electrocardiogram (ECG) measures of left ventricular hypertrophy were recorded:  QRS voltage 
sum, QRS voltage sum product, Cornell product and Sokolow-Lyon index as well as PR interval
10.1161/CIRCULATIONAHA.116.026560
8 
(see Supplemental Method 1 for definitions). Cardiometabolic traits that were not normally 
distributed were transformed to the natural logarithmic scale. For comparability across 
biomarkers, measurements were z-score standardised. Self-reports of current smoking status 
(ever/ never) and alcohol consumption (drinker/ non-drinker) were considered to be potential 
confounders of adiposity-cardiovascular disease (CVD) associations.  
Genotyping
Supplemental Table 1 details genotyping by study. Genotyping in all UCLEB studies was 
conducted with the Metabochip array (except a subset of ELSA study that used a GWAS 
array)25. The remaining studies used GWAS arrays (HRS, PROSPER) or Exome Chip (NEO). 
Individuals were excluded from the analyses on the basis of gender mismatch, excessive or 
minimal heterozygosity, relatedness or individual missingness (>3%). Individuals of non-
European ancestry were removed to minimise confounding by population structure. SNPs with a 
low call rate or evidence of departure from Hardy–Weinberg equilibrium were excluded from 
analyses (see Supplemental Table 1 for thresholds employed in different studies).  
Statistical Analyses 
Observational Analyses 
In individual participant data studies adiposity (BMI or WHRadjBMI) was z-score standardised 
and linear or logistic regression models were fitted for each cardiometabolic trait or disease 
outcome.  Observational models were adjusted for age and sex. Fixed-effect meta-analyses were 
employed to derive combined observational estimates across studies. We calculated I2 statistics 
to quantify heterogeneity between studies and derived P-values from Cochran’s Q test26.  
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Genetic Analyses
SNP selection and construction of the genetic instruments 
Selection of SNPs for the genetic instruments was based on analyses from the Genetic 
Investigation of ANthropometric Traits (GIANT) consortium, which included 339,224 
individuals from 125 separate studies for BMI17 and 224,459 individuals from 101 studies for 
WHRadjBMI18.  These studies identified 97 independent SNPs for BMI and 49 independent 
SNPs for WHRadjBMI at GWAS significance. We found no overlap between the BMI SNPs and 
WHRadjBMI SNPs. In studies where the SNP identified by GIANT was not available in the 
Metabochip array, we used proxy SNPs in linkage disequilibrium (R2>0.8) with the specified 
SNP. Details of proxy SNPs used by platform (Metabochip/ GWAS) are given in Supplemental
Tables 3 and 4. 
Genetic association analyses in individual participant data
We performed a within study genetic association analysis with adiposity (standardised BMI and
WHRadjBMI) as a continuous trait using an additive model. We used linear or logistic 
regression models to estimate the additive effect of each SNP on cardiometabolic traits and 
outcomes. We used logistic regression to test the association of each SNP with smoking and 
alcohol consumption as potential confounders of the adiposity-CVD association.  
Instrumental variable analyses in summary data 
We conducted three tests for the causal estimation of each adiposity measure on cardiometabolic 
outcomes: 1) Inverse-variance weighted method (IVW), 2) MR-Egger and 3) Weighted median. 
In the absence of horizontal pleiotropy, we would expect all three tests to give consistent results.
All IV estimates in summary data were calculated using the mrrobust package (available from 
https://github.com/remlapmot/mrrobust) in Stata version 1427, 28. The proportion of variance in 
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adiposity explained by the genetic instruments in summary data was calculated using the 
grs.summary function from the gtx package in R29, 30. A threshold of statistical significance of 
P<0.025 (0.05/2=0.025) was used to reflect testing for two different adiposity traits (BMI and 
WHRadjBMI).
1) IVW instrumental variable analyses
To combine data across studies with summary level data we pooled the association of each SNP 
on risk of each CVD outcome/ cardiometabolic trait using fixed effects meta-analysis. To 
provide external weights for the SNP-adiposity associations, the effect of each SNP on adiposity 
(BMI; WHRadjBMI) in GIANT was pooled with that in all other contributing studies, excluding 
studies that had already contributed to GIANT (1958BC, EAS, HRS, NSHD, PROSPER,
Whitehall II). To quantify heterogeneity in the SNP effects across studies we calculated I2 and 
derived P-values from Cochrane’s Q tests. All P-values were two-sided.  Inverse-variance 
weighted meta-analysis (IVW) was used to provide a combined estimate of the causal estimates
(SNP-outcome/ SNP-adiposity) from each SNP. IVW is equivalent to a two-stage least squares 
or allele score analysis using individual-level data, and is hence referred to here as “conventional 
MR”31. However, it can lead to over-rejection of the null, particularly when there is 
heterogeneity between the causal estimates from different genetic variants.
2) MR-Egger instrumental variable analyses 
To account for potential horizontal pleiotropy in the multi-SNP adiposity instruments, we re-
estimated the instrumental variable associations using MR-Egger regression10, 11. MR-Egger tests 
for presence of, and accounts for, unbalanced pleiotropy by introducing a parameter for this 
bias10. Specifically, linear regression of the instrument-outcome effects is performed on the 
instrument-exposure effects, with the slope representing the causal effect estimate and the 
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intercept the net bias due to horizontal pleiotropy. An additional assumption is required that the 
individual SNP effects on the exposure are independent of their pleiotropic effects on the 
outcome (termed the ‘InSIDE assumption’)12.  
3) Weighted median estimate instrumental variable analyses 
Finally, we applied a complementary approach termed the weighted median estimator which can 
give valid estimates even in the presence of horizontal pleiotropy provided at least half of the 
weighted variance is valid12.   
Power calculations
Power to detect causal estimates was calculated based on the proportion of variance of the 
exposure explained by the instruments (R2), the total number of individuals in the analysis, and 
the number of cases and controls using the online tool http://cnsgenomics.com/shiny/mRnd/32.
Power estimates are provided in (Supplemental Table 5). 
Results
Studies and participants
Full descriptive details of the included studies are given in Supplemental Table 1.  Data from
14 prospective studies and randomised trials and four consortia were included with 66,842 CHD 
cases (3,716 from UCLEB/ other non-consortia studies), 12,389 ischaemic stroke cases and 
34,840 T2D cases. The number of individuals included in the analyses of cardiometabolic traits 
ranged from 6,625 to 213,556. The mean age in individual participant data  studies was 63.5 
years, the mean BMI 27.4 kg/m2 (SD 4.6) and the mean WHR 0.89 (SD 0.13) (Supplemental
Tables 1 & 6). Distribution of binary traits by study are given in Supplemental Table 7.
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Instrument validation 
We identified Metabochip proxies for 13 BMI SNPs and 7 WHRadjBMI SNPs; the median R2
was 0.965 & 0.913 respectively (Supplemental Tables 3 and 4). The proportion of variance of 
BMI explained by the BMI genetic instrument was 1.7% while the WHRadjBMI instrument 
explained 0.7% WHRadjBMI variance. The associations of individual SNPs with adiposity are 
shown in Supplemental Tables 8 and 9.  
Mendelian randomization analysis of adiposity with cardiometabolic traits
Figure 1a/b presents estimates of associations between BMI and WHRadjBMI with 
cardiometabolic traits from IV analyses. Both genetically instrumented adiposity measures were
found to be causally associated with increased insulin and triglycerides. In addition, BMI was 
causally associated with higher IL-6, with a directionally consistent result identified for 
WHRadjBMI. Both adiposity measures were also causally associated with decreased levels of 
HDL-C. However, only WHRadjBMI was associated with increased LDL-C, and the association 
with SBP was also stronger. BMI was inversely associated with albumin, while WHRadjBMI
was not; but heterogeneity across studies was moderately high (I2=57%).  
 There was evidence for a causal association with some of the ECG measures that index 
left ventricular hypertrophy with both adiposity measures associated with higher log Cornell 
Product; in addition BMI, but not WHRadjBMI associated with lower Sokolow-Lyon index.
There was no suggestion for a causal association of either measure of adiposity and PR interval.  
Both WHRadjBMI and, to a weaker extent, BMI were causally associated with higher CIMT
(39%, 95%CI: 9%, 77% and 18%, 95% CI: 1%, 38% higher per SD in WHRadjBMI and BMI,
respectively). WHRadjBMI had a weak association with lung function (FEV1:FVC) at 0.12 units 
per SD (95%CI 0.01, 0.24), but the P-value of 0.04 does not meet the threshold which takes into 
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account testing for multiple measures of adiposity. There was no suggestion of a causal
association of either adiposity measure with any of the measures of renal function.
With MR-Egger regression there was no convincing evidence for directional pleiotropy in any of 
the associations of adiposity traits with continuous cardiometabolic traits (Supplemental Tables 
10 and 11).
Supplemental Figures 2a/b illustrate the consistency of observational and IV estimates for 
associations between adiposity and cardiometabolic traits (Supplemental Tables 12 and 13).
Mendelian randomization analysis of adiposity with cardiometabolic diseases 
Figures 2a-c show the association of each adiposity measure with CHD, ischaemic stroke and 
T2D from conventional IVW and weighted median MR analyses. MR-Egger estimates tended to 
be much more imprecise and are therefore presented separately in Supplemental Table 14 to 
facilitate interpretation.
Mendelian randomization analysis of adiposity with CHD  
The summary causal estimate per 1SD increment in BMI from conventional IVW MR was an 
OR for CHD of 1.36 (95%CI: 1.22, 1.52) (Figure 2a). MR-Egger regression suggested little 
evidence for unbalanced pleiotropy in the genetic instrument (intercept P-value=0.65), and both 
MR-Egger and weighted median estimates were consistent with the IVW estimate
(Supplemental Figure 3a). Furthermore, MR estimates were consistent with observational 
estimates reported by the Emerging Risk Factors Collaboration (Figure 2a) 
 Similarly, we found an association between WHRadjBMI and CHD using conventional 
MR (OR 1.48, 95% CI 1.28, 1.71 per SD WHRadjBMI, Figure 2a and Supplemental Figure 
3b). The intercept for the MR-Egger test was 0.0134 (95%CI -0.0004, 0.0278; P-value=0.06). 
The causal estimate from MR-Egger was imprecise (OR 0.89, 95% CI 0.52, 1.53), but the 
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weighted median estimator (which retains more power than MR-Egger) provided a causal effect
of 1.61 (95% CI 1.36, 1.90) which was consistent with the IVW result.
Mendelian randomization analysis of adiposity with ischaemic stroke  
The causal OR for the association between BMI and ischaemic stroke was 1.09 (95%CI 0.93, 
1.28 per SD) (Figure 2b). Results from the MR-Egger analysis were compatible with no 
unbalanced pleiotropy (intercept P-value=0.73), and the weighted median estimator suggested no 
causal association (Supplemental Figure 3c). Estimates for association between BMI and stroke 
sub-types were imprecise and 95% confidence intervals all included the null (Table 1). Thus, 
while all IV estimates for BMI and stroke include the Emerging Risk Factors Collaboration 
estimate (Figure 2b), lack of precision hinders any clear causal evidence for an association 
between BMI and ischaemic stroke.
 Results do, however, provide some evidence for a causal association of WHRadjBMI 
with ischaemic stroke (OR 1.32, 95%CI 1.03, 1.70 per SD in WHRadjBMI) (Figure 2b). MR-
Egger regression was consistent with no unbalanced pleiotropy (intercept P-value=0.94), and the 
weighted median estimator was very close to the IVW estimate (causal OR 1.34, 95%CI 0.97, 
1.86 per SD increase in WHRadjBMI) (Supplemental Figure 3d). Limited evidence was found 
for a causal association with stroke sub-types; all point estimates were consistently above one but 
precision was poor and 95% confidence intervals included the null (Table 1).   
Mendelian randomization analysis of adiposity with T2D  
We found a causal OR for T2D of 1.98 (95%CI: 1.41, 2.78) per SD increase in BMI (Figure 2c). 
Similar but stronger estimates were identified using MR-Egger (OR 3.70, 95% CI 1.63, 8.41; P-
value for pleiotropy=0.10) and weighted median estimator (OR 2.70, 95% CI 2.26, 3.23). One 
BMI SNP (rs7903146) was an outlier (Supplemental Figure 3e) and is a marker for 
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the TCF7L2 gene, a GWAS-identified locus for T2D33. We therefore repeated the T2D analysis 
excluding rs7903146 (Supplemental Table 15 yielding an IVW OR of 2.25 (95%CI: 1.87, 2.71) 
per SD increase in BMI, with similar estimates from MR-Egger and weighted median estimators. 
Likewise, we found a causal relationship between WHRadjBMI and T2D (OR 1.82, 95% CI 
1.38, 2.42 per SD increase in WHRadjBMI, Figure 2c). MR-Egger did not provide evidence of 
unbalanced pleiotropy (P-value for pleiotropy=0.21), and the weighted median estimator result 
was consistent with the IVW (OR 1.64, 95% CI 1.25, 2.15) (Supplemental Figure 3g).
Multivariate Mendelian randomization 
We found some evidence for association of both adiposity instruments with smoking, but not 
with other major confounders (Supplemental Table 16). To account for this, sensitivity analyses 
were undertaken for each cardiometabolic disease using multivariate MR including the effect of 
each SNP used as instrument for BMI and WHRadjBMI on smoking. MR estimates were found 
to be robust to this adjustment (Supplemental Table 17), with generally consistent point 
estimates measured with greater imprecision reflecting the reduced power in these analyses. The 
multivariate MR (adjusted for smoking) for the causal association of WHRadjBMI with 
ischaemic stroke was 1.27 (95% CI 0.84-1.93) broadly similar to 1.32 (95% CI 1.03-1.70) in the 
main IVW analysis, but with a wider confidence interval. We also included FEV1:FVC in these 
sensitivity analyses due to the likely association of this trait with smoking; again adjusted results 
were very similar to the main IVW results (Supplemental Table 17).
Discussion
We conducted the most comprehensive MR analysis to date comparing the causal role of central 
and general adiposity in the development of multiple cardiovascular disease outcomes (CHD, 
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multiple stroke sub-types and T2D). Owing to benefits of MR to minimize residual confounding 
by common lifestyle factors and underlying ill-health, we are able to quantify that one standard 
deviation increase in genetically instrumented WHRadjBMI (~0.08 units) results in a ~50% 
increase in risk of CHD independent of BMI. This compares with the ~40% increase in risk of 
CHD we find per 1SD increase in genetically instrumented BMI (~4.6 kg/m2) which is 
consistent with the observational effect derived from large prospective population cohorts 
including the Emerging Risk Factors Collaboration 1 (CHD HR 1.29 [1.22-1.37] per 1SD) and 
the Prospective Studies Collaboration33 Thus, while observational studies such as the Emerging 
Risk Factors Collaboration  have found risk to be consistent across different measures of 
adiposity, our results suggest WHRadjBMI may have a stronger effect, although the greater 
imprecision in the MR estimates should also be considered.  
 Similarly, while observational studies have found different measures of adiposity to have 
similar associations with risk of ischaemic stroke1, our result again suggest that WHRadjBMI 
may be more strongly associated (increased risk ~30% per 1SD). Recent findings from 
INTERSTROKE also suggest that WHR is a much stronger deleterious risk factor for ischaemic 
stroke5.  Our SBP results follow a similar pattern, with a much stronger association between 
central adiposity and SBP than general adiposity. This is also the first MR study to suggest 
potential causal association between central adiposity ischaemic stroke subtypes, and CIMT, a 
widely used surrogate measure of sub-clinical atherosclerosis. 
 Previous adiposity MR studies used limited numbers of SNPs, (with weaker genetic 
instruments), fewer events and generally failed to find evidence for a causal association between
BMI and CHD19, 21. However, one MR study using a 3-SNP allele score (FTO, MC4R,
TMEM18) reported an OR of 1.52 (95% CI 1.12-2.05 for a 4 kg/m2 increase in BMI20 , and most 
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recently a MR study using a 32-SNP instrument for BMI found similar results for CHD to ours22.
We do not however replicate the causal association between BMI and ischaemic stroke reported 
by the same study (hazard ratio per SD-increase of BMI 1.83; 95% CI 1.05-3.20)22, despite 
increasing the number of stroke cases tenfold. Furthermore, our results are in line with those for 
ischaemic stroke from the Emerging Risk Factors Collaboration and INTERSTROKE, including 
the apparently stronger association we find between central adiposity and stroke relative to 
general adiposity. Results for the causal association of WHRadjBMI with CHD and T2D are 
consistent with those from a recent MR analysis34.
We present the largest number of cardiometabolic traits ever examined in a MR analysis 
of adiposity. The current findings are broadly consistent with earlier MR studies for glucose, 
triglycerides, HDL-C, SBP, and IL-6, providing further support for a detrimental impact of 
adiposity on the cardiovascular system19, 21, 23. However, we find no evidence for a causal 
association between BMI and LDL-C, consistent with some but not all earlier studies21, 23. A 
recent MR study found a causal effect of BMI and a wide range of lipid metabolites, including 
all LDL metabolites35, but was conducted in a younger, healthier population (average BMI 
~24kg/m2) than is commonly included in MR studies (including the current one) and this could 
explain the discrepancy with our findings (as observational studies suggests the association of 
BMI and LDL-C plateaus beyond 27kg/m2) 33. We also report novel positive causal associations
of adiposity with the ECG measure log Cornell product (a measure of left ventricular 
hypertrophy; LVH). The negative association of BMI with Sokolow Lyon (an alternative 
measure of LVH) was unexpected and may represent a false positive. While both log Cornell 
product and Sokolow Lyon measure left ventricular hypertrophy, log Cornell product is 
considered to be the better test for identifying LVH when measured against a gold standard36. 
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 This study demonstrates that central obesity (as quantified by WHRadjBMI) has a causal 
effect on CHD that is independent of BMI. This finding demonstrates the potential of MR 
approaches for investigating highly correlated adiposity measures that have proved challenging 
to disentangle in observational studies37. In these analyses we find that WHRadjBMI has a more 
deleterious lipid profile than BMI, with detrimental associations of greater magnitude with 
triglycerides and HDL-C and association with LDL-C not found for BMI. The association of 
WHRadjBMI with CIMT is also of greater magnitude. Conversely, BMI appears to have a 
greater inflammatory effect than WHRadjBMI, and potentially a stronger effect on the ECG 
measures that index left ventricular hypertrophy as well as with glucose and T2D. The apparent 
lack of association of WHRadjBMI with glucose is surprising, but is potentially explained by a
negative association of WHRadjBMI SNPs with BMI. Interestingly, a recent paper showed 
WHRadjBMI to associate with 2-hour fasting glucose suggesting that WHRadjBMI may have 
differential effects according to how glucose is measured; different mechanisms are likely to 
regulate fasting and 2-hour glucose34. In keeping with our findings, the discovery GWAS that 
identified 49 SNPs associated with WHRadjBMI18 found associations of the SNPs with 
concentrations of HDL-C, TG, LDL-C, adiponectin and fasting insulin. Furthermore, the study 
identified enrichment of WHRadjBMI SNPs for T2D and CHD.  
 This study suggests that it is not only the volume of adiposity, but also its location, that is 
relevant for disease, lending weight to the emerging theory that the deposition of body fat plays 
important roles that are independent of total fat. For example, at a given BMI, there is 
considerable inter-individual variation in the amount of visceral fat, which shows associations 
with disease38. Our results also suggest that efforts to quantify the effect of adiposity on burden 
of disease should include multiple measures of adiposity to avoid underestimating the true 
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burden of adiposity on health39. As regards specific interventions that focus WHR more than 
BMI, there is observational evidence that physical activity can modify WHR independent of 
BMI40. Thus it may be possible to mitigate the effects of WHR through increased population-
wide physical activity. In addition, our findings open potentially new avenues of investigation. 
For example, identifying these causal effects of WHRadjBMI can enable research to focus on the 
downstream consequences of this trait, and potentially identify traits (such as metabolites)35 that 
could mediate the relationship between WHRadjBMI and disease which may themselves be 
amenable to pharmacological modification. Such traits downstream of WHRadjBMI could be 
unique (and not shared with BMI) raising the possibility of novel opportunities for drug 
discovery and disease prevention.  
Strengths
This study has many strengths. First, independent multi-SNP instruments comparing the effect of
central and general adiposity on multiple CVD outcomes; second, the use of powerful genetic 
instruments for BMI and WHRadjBMI which explained up to twice the phenotypic variation 
compared with previous MR studies; third, large number of clinical events that provided ample 
power to detect the associations of adiposity with cardiometabolic diseases fourth, the use of 
methods to minimise the impact of unbalanced pleiotropy in the genetic instruments that may 
invalidate findings from conventional MR.  
 In addition to this being the most comprehensive evaluation of adiposity-related traits 
with cardiovascular and metabolic risk factors and diseases, our analysis also facilitates their 
direct comparison, and therefore contrasts the effects of general adiposity with body fat 
distribution in the same datasets. This provides novel insights, demonstrating that WHRadjBMI 
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is more relevant to the development of subclinical atherosclerosis and stroke compared to BMI, 
whereas both BMI and WHRadjBMI are important for CHD and diabetes. 
Limitations
Limitations include the potential pleiotropic effects of the multi-SNP instruments. However, 
results suggest little evidence for unbalanced pleiotropy. Re-estimates of the causal associations
using MR-Egger regression were broadly consistent with our conventional MR analysis, albeit 
with a loss of precision and consequently a loss of power, while weighted median estimates (that 
retains more power than MR-Egger) proved remarkably similar to IVW.   
The InSIDE (Instrument Strength Independent of Direct Effect), which is untestable, 
assumes that the pleiotropic effects of the genetic variants are uncorrelated with the association 
of the genetic variants with the exposure. Violation of InSIDE would give rise to biased causal 
estimates from MR-Egger; however each MR approach has different strengths and assumptions, 
for example, violation of InSIDE does not affect the weighted median MR approach 12. This 
highlights the importance of using the three MR approaches (IVW, median and MR-Egger) in 
our study. General concordance of MR estimates derived from these approaches helps reinforce 
the conclusions that can be drawn.   We used a multi-SNP instrument for WHR that had already 
been adjusted for BMI as part of the GIANT GWAS18. Genetic instruments for phenotypes 
adjusted for heritable components may show association with the adjusted phenotype through 
collider bias41, which could violate the InSIDE assumption. Indeed, we found WHRadjBMI 
SNPs to be associated with BMI beyond what would be expected by chance (Supplemental
Table 18). This could lead to biased results; however in the current scenario the bias will tend to
be towards the null (and underestimate the true effect) as the WHRadjBMI SNPs are associated 
negatively with BMI. 
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 We selected cardiometabolic traits a priori on the basis that previous studies have shown 
them to be observationally and genetically associated with BMI. Therefore, although we test 
multiple outcomes use of a conventional Bonferroni would over-penalize the interpretation.
Future studies should look to include emerging CVD outcomes such as heart failure and atrial 
fibrillation, and consider additional potential confounders. In addition, more stroke cases should 
be added to improve precision in these analyses, in particular for multivariate MR analyses. 
Given that our MR analysis on CHD was largely based on summary data, we were unable 
undertake more detailed investigations of the linear relationship between BMI or WHRadjBMI 
and risk of CHD and/ or to explore the causal effects of very low levels of BMI or WHR on 
CHD42. These are important next steps to investigate, given the uncertainty regarding whether 
the U-shape association of BMI with disease reflects a true causal relationship, or whether it is 
an artefact from residual confounding and/or underlying ill-health. The recent finding of a J-
shaped (rather than U-shaped) association between BMI and mortality in healthy non-smokers 
reinforces the likely role of artefact this association43. Therefore, application of methods for non-
linear MR could help to determine the true optimal level of BMI for health44. However, such 
analyses would require access to individual participant data in all studies.  
Finally, although we identify several downstream biological mechanisms by which 
general and central adiposity may mediate the effects on risk of CHD, these results should be 
considered as exploratory and further studies using adequate methodology for mediation analysis 
should be conducted45, 46, including the analysis of finer resolution for cardio-metabolic traits for 
example using NMR metabolomics.
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Conclusions
Our study supports evidence for a causal role of both central and general adiposity in risk of 
CHD and T2D, and central adiposity in risk of ischaemic stroke. Furthermore, our results suggest 
that central adiposity may pose higher risk for stroke and CHD. Efforts to estimate the role of 
adiposity on cardiovascular disease should consider the potential independent effects of different 
measures of adiposity. 
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Table 1. Mendelian randomization estimates for the association of adiposity and stroke sub-
types
IVW Weighted median
OR LCI UCI I2 P(Genetic pleiotropy) OR LCI UCI
BMI
All ischaemic stroke 1.09 (0.93, 1.28) 20% 0.734 0.98 (0.77, 1.25)
- Cardioembolic 1.18 (0.89, 1.55) 0% 0.507 1.40 (0.87, 2.24)
- Large vessel disease 1.14 (0.82, 1.59) 19% 0.625 1.12 (0.65, 1.91)
- Small vessel disease 0.93 (0.64, 1.35) 30% 0.270 1.15 (0.67, 1.97)
Haemorrhagic stroke 1.51 (0.73, 3.13) 0% 0.435 1.28 (0.37, 4.40)
WHRadjBMI
All ischaemic stroke 1.32 (1.03, 1.70) 38% 0.936 1.34 (0.96, 1.87)
- Cardioembolic 1.24 (0.84, 1.83) 0% 0.588 1.32 (0.73, 2.38)
- Large vessel disease 1.37 (0.90, 2.09) 0% 0.470 0.87 (0.48, 1.58)
- Small vessel disease 1.57 (0.98, 2.51) 13% 0.861 1.71 (0.89, 3.29)
Haemorrhagic stroke 1.89 (0.69, 5.18) 0% 0.430 1.73 (0.42, 7.06)
IVW: inverse variance weighted (also termed ‘conventional’ MR) and weighted median. P(genetic 
pleiotropy) relates to the P-value derived from the intercept of MR-Egger; a small P-value denotes 
presence of directional pleiotropy.
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Figure Legends
Figure 1a. Association of BMI with continuous biomarkers derived from Mendelian 
randomization analysis. Values represent standardized mean differences of each trait per SD 
increase in BMI derived from conventional (IVW) Mendelian randomization analysis. Non-
normally distributed variables were natural ln transformed; therefore mean differences displayed 
on the log scale may be anti-logged and interpreted as percentage differences in SD of trait per 
SD in BMI. Log triglycerides from individual participant data studies only; GLGC triglycerides 
in Supplemental Table 10.
Figure 1b. Association of WHRadjBMI with continuous biomarkers derived from 
Mendelian randomization analysis. Values represent standardized mean differences of each 
trait per SD increase in WHRadjBMI derived from conventional (IVW) Mendelian 
randomization analysis. Non-normally distributed variables were natural log transformed; 
therefore mean differences displayed on the log scale may be anti-logged and interpreted as 
percentage difference in SD of trait per SD in WHRadjBMI. Log triglycerides from individual 
participant data studies only; GLGC triglycerides in Supplemental Table 11. 
Figure 2a. Associations of adiposity with risk of CHD from observational and Mendelian 
randomization analyses. Association between coronary heart disease and adiposity (BMI and 
WHRadjBMI) comparing causal odds ratios (OR) per SD of adiposity trait derived from 
instrumental variable analysis and observational analysis from the Emerging Risk Factors 
Consortium hazard ratio (HR per SD of BMI or waist:hip adjusted for age, sex and smoking 
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status)1. Causal estimates are derived from Mendelian randomization and include conventional 
(ratio) approach and weighted median (see Methods for further details). P(genetic pleiotropy) 
relates to the P-value derived from the intercept of MR-Egger; a small P-value denotes presence 
of directional pleiotropy.
Figure 2b. Associations of adiposity with risk of ischaemic stroke from observational and 
Mendelian randomization analyses. Association between ischaemic stroke and adiposity (BMI 
and WHRadjBMI) comparing causal odds ratios (OR) per SD of adiposity trait derived from 
instrumental variable analysis and observational analysis from the Emerging Risk Factors 
Consortium (HR of ischaemic stroke per SD of BMI or waist:hip adjusted for age, sex and 
smoking status)1. Causal estimates are derived from Mendelian randomization and include 
conventional (ratio) approach and weighted median (see Methods for further details). P(genetic 
pleiotropy) relates to the P-value derived from the intercept of MR-Egger; a small P-value 
denotes presence of directional pleiotropy.
Figure 2c. Associations of adiposity with risk of T2D from observational and Mendelian 
randomization analyses. Association between T2D and adiposity (BMI and WHRadjBMI) 
comparing causal odds ratios (OR) per SD of adiposity trait derived from instrumental variable 
analysis and observational analysis from Vazquez et al., 20072. Causal estimates are derived 
from Mendelian randomization and include conventional (ratio) approach and weighted median 
(see Methods for further details). P(genetic pleiotropy) relates to the P-value derived from the 
intercept of MR-Egger; a small P-value denotes presence of directional pleiotropy.





